A Pilot Study of Genetic Testing Uptake Through Enhanced Oncology Nurse-Led Intervention

Launched by UNIVERSITY OF CALIFORNIA, DAVIS · May 28, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring a new way to help cancer patients understand the importance of genetic testing, which can identify inherited risks for certain types of cancer. Researchers believe that by enhancing the education provided by oncology nurses during treatment discussions, they can encourage more patients to undergo genetic testing. This is important because knowing one’s genetic risks can lead to better treatment options and inform family members about their own risks. The study is looking for adults aged 18 and older who have been diagnosed with specific solid tumors, are starting or switching cancer treatments, and have not previously had genetic testing since 2014.

Participants in this study can expect to receive additional support and information from their oncology nurses about genetic testing and how it may benefit their treatment. The goal is to see if this approach makes it easier for patients to understand and pursue genetic testing. It’s important to note that not everyone will be eligible; for instance, patients who have already had genetic testing since 2014 or who have certain medical conditions may not be able to participate. This trial is actively recruiting participants, and those who join will play a key role in helping to improve cancer care and education for future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adults (≥ 18 years)
• • Diagnosed with a solid tumor cancer type that has established guidelines suggesting the utility of genetic testing in treatment (breast, ovarian, prostate, pancreatic, colon, Lynch syndrome-related cancers (colorectal, endometrial, gastric, ovarian, pancreatic, urothelial, brain (usually glioblastoma), biliary tract, small intestine), Li-Fraumeni syndrome tumor spectrum (e.g., soft tissue sarcoma, osteosarcoma, central nervous system tumors, breast cancer, adrenocortical carcinoma), etc.)
• • Eligible for GCT based on the current NCCN guidelines
• • Starting new systemic therapy or switching systemic therapy
• • Eligible for GCT as per the current NCCN guidelines
• • No prior genetic testing (or tested before 2014)
• Exclusion Criteria:
• • Prior GCT with test results available (if tested 2014 onwards)
• • Patients scheduled for treatment education with Advanced Practice Provider (typically reserved for more complex regimens)
• • Patients with cognitive impairments or severe psychological disorders that would limit their ability to understand the genetic counseling/testing information or give informed consent.
• • Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures (e.g., patients requiring urgent therapy and/or inpatient chemotherapy initiation).
• • Patients who are currently participating in other clinical trials that could confound the outcomes of genetic testing uptake.
• • Prospective participants who, in the investigator's opinion, may not be able to comply with all study procedures (including compliance issues related to logistics).
• • Hematologic malignancy

Trial Officials